Idorsia Ltd (SWX:IDIA)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 259.73M |
| Revenue (ttm) | 112.51M |
| Net Income (ttm) | -263.76M |
| Shares Out | 224.29M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101,943 |
| Average Volume | 616,597 |
| Open | 1.162 |
| Previous Close | 1.158 |
| Day's Range | 1.122 - 1.162 |
| 52-Week Range | 0.612 - 2.980 |
| Beta | 1.54 |
| RSI | 61.42 |
| Earnings Date | Apr 30, 2025 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat... [Read more]
Financial Performance
In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.
Financial StatementsNews
Idorsia publishes its Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report...
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
Allschwil, Switzerland – March 14, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in...
Idorsia Ltd (IDRSF) Q4 2024 Earnings Call Transcript
Idorsia Ltd 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Idorsia Ltd in conjunction with their 2024 Q4 earnings call.
Idorsia announces financial results for 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2024.
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia's outstanding convertible bond d...
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025 Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed...
Idorsia publishes the resolutions for the upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted upon Unaudited Financi...
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fun...
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders
Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland – January 15, 2025...
Idorsia publishes an invitation to a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on January 1...
Idorsia to call for a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025 Idorsia Ltd (SIX: IDIA) today announced that – in the coming days – the company intends to publish an invitation to...
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreement Company in discussions with bondholders to restructure the company's outstan...
Swiss pharma firm Idorsia plans debt restructuring, job cuts
Idorsia plans to restructure its debt, implement cost-cutting measures and could shed up to 270 jobs in a bid to spur profitability, the Swiss pharma company said on Wednesday.
Idorsia enters into exclusive negotiations for global rights to aprocitentan
Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentan Company to streamline the business, resulting in cost ...
Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension
Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients wh...
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of syst...
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults wi...
Amended terms of Idorsia's 2024 convertible bonds become effective
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal wa...
Idorsia Ltd (IDRSF) Q2 2024 Earnings Call Transcript
Idorsia Ltd (OTC:IDRSF) Q2 2024 Earnings Conference Call July 27, 2024 9:00 AM ET Company Participants Andrew Weiss - Senior Vice President, Head of Investor Relations & Corporate Communications Andre...
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
Allschwil, Switzerland – July 1, 2024 Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adul...
Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality' category
Allschwil, Switzerland – June 21, 2024 Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize i...
Idorsia holds its Annual General Meeting of Shareholders
Allschwil, Switzerland – June 13, 2024 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Direc...